GlassScriptPhysician profile
Adam Joseph Rush
NPI 1528095643
$3,290.09
in general payments reported to CMS, 2019-2025
10 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $53.84 · 2021: $276 · 2022: $97.00 · 2023: $1,871 · 2024: $436 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.31 |
| Travel and Lodging | $641.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,669.52 | 2021-2023 | Synchromedii |
| Abbvie INC. | $859.37 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Medtronic USA, INC. | $248.38 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $195.55 | 2022-2024 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $115.13 | 2024-2025 | Belbuca |
| Allergan, INC. | $83.23 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $63.29 | 2019-2022 | |
| Lilly USA, LLC | $20.21 | 2024 | Emgality |
| Fidia Pharma USA INC. | $19.04 | 2023 | Hymovis |
| Dynasplint Systems INC. | $16.37 | 2025 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.